Medtech Insight award winner picks up OBN prize
DNAe has been named the ‘Best Diagnostic Medtech Company’ at the 2018 OBN Awards.
The company was recognised for its semiconductor DNA analysis and sample preparation technologies, including its development of a test for bloodstream infections (BSI) that can lead to sepsis.
It was chosen ahead of Oxford Cancer Biomarkers, Owlstone Medical and Inivata by a panel of judges made of UK and global life sciences stakeholders.
The award follows the company's success at the Medtech Insight awards in Philadelphia in September where it was
named the ‘Most Innovative Team or Innovator of the Year’.
Jonathan Rohll, head of business information at OBN said: “DNAe really caught the eye of many of our judges for addressing a clear unmet need with their novel microchip-based, fast and simple technology platform that has huge potential in the early diagnosis of sepsis and other acute conditions. We would like to congratulate them on winning the Best Diagnostic Medtech Company category at the 2018 OBN Awards.”
DNAe’s LiDia BSI test is designed to help medical professionals to treat antimicrobial resistant infections by identifying the causative pathogen, including key antimicrobial resistance markers within two to three hours from a whole blood sample.
Nick McCooke, chief business officer of DNAe, said: “We are very proud to be named as Best Diagnostic MedTech Company at the 2018 OBN Awards. Identification of bloodstream infections using current standard- of-care culture-based diagnostics is slow, and testing is often carried out at specialist laboratories away from the patient. Meanwhile, treatment is typically empirical, impacting survival rates and hospital stay negatively. DNAe’s first generation platform and revolutionary test, currently in development, will enable rapid diagnosis of sepsis-causing bloodstream infections closer to the frontline of care, and operated by non-expert end users. The potential impact to patients and institutions from timely evidence-based treatment owing to our approach is considerable.”
Dr Steve Allen, CEO of DNAe Group Holdings added: “We are delighted that DNAe is named as Best Diagnostic MedTech Company at the 2018 OBN Awards and we thank the Expert Judges for this special honour. Being recognised in short order in two separate prestigious industry award programs, now by the OBN Awards and last month by the MedTech Insight Awards, follows a successful first half of the year for DNAe. In April, at the ECCMID 2018 congress, we previewed a demonstration of the blood-to-result workflow of LiDia BSI for the first time at our booth, and presented data that demonstrated the ability of the LiDia BSI method to detect pathogens and antibiotic resistance in samples from patients who had received antibiotic therapy, within a significantly shorter period than standard-of-care blood culture testing. We look forward to making further announcements in due course.”